Bioniche Bladder Cancer Drug Fast Tracked By FDA
Posted on: Friday, 5 May 2006, 21:04 CDT
The FDA has granted fast track designation to Bioniche Life Sciences' Urocidin for the treatment of non-muscle invasive bladder cancer in patients who are unresponsive to the current standard therapy.
The standard chemotherapy for the condition is bacillus calmette-guerin (BCG), a live, attenuated strain of mycobacterium bovis, a therapy that is often associated with treatment-limiting side effects.
In February the FDA approved the company's 105 patient North American phase III clinical trial with Urocidin in the treatment of this (unresponsive to BCG) patient population.
Fast Track designation means that, when data from the phase III program becomes available, the company could expect an expedited review of its biologics licensing application for Urocidin.
"A large number of patients don't respond to BCG - approximately 35% - and have not previously had a satisfactory alternative treatment beyond bladder removal, an invasive and life-altering surgery. This designation gives us great confidence that Urocidin will be available to uro-oncologists for their refractory patients at the earliest possible opportunity," said Graeme McRae, president & CEO of Bioniche.
The trial in patients unresponsive to BCG is one of two trials in Bioniche's phase III program with Urocidin. The second will involve approximately 630 patients and will compare Urocidin to BCG as first-line therapy in non-muscle invasive bladder cancer at high risk of recurrence or progression.
Source: Datamonitor
Related Articles
- Repligen Announces Completion of Patient Treatment in Phase 3 Clinical Trial of RG1068 in MRI Imaging of the Pancreas
- Positive CHMP Opinion for JAVLOR(R) in Metastatic Treatment of Bladder Cancer After Failure of a Prior Platinum-Containing Regimen
- Intense Treatment Doesn’t Boost Chances for Patients With Early Bladder Cancer
- Bioniche Granted Fast Track Status for Bladder Cancer Therapy
- Oculus Completes Patient Treatment in Phase II Diabetic Foot Ulcer Trial
- Oculus Innovative Sciences Completes Patient Treatment and Follow-Up in Its Phase II Clinical Trial in Mildly Infected Diabetic Foot Ulcers
- Viventia Initiates Patient Treatment in Bladder Cancer Trial
- Peregrine Initiates Patient Treatment in Bavituximab Combination Therapy Cancer Trial
- Odyssey Pharmaceuticals and Indevus Pharmaceuticals Announce Odyssey's Plans to Initiate Phase IV Open Label Study of the Effectiveness and Safety of SANCTURA in Patients With Overactive Bladder Symptoms
- ImClone Systems Commences Patient Treatment in U.S. Phase I Clinical Trial Of IMC-1121B
 |
 |
User Comments (0)
RSS Feeds